Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
A contract API manufacturer explains how to build with cGMP in mind.
August 22, 2005
By: Ralph Tyree
Ph.D.
Pisgah Labs is a custom manufacturer of high purity fine chemicals for a variety of customers. When we decided to enter the Active Pharmaceutical Ingredient (API) market, we embarked on the planning and implementation process to provide a “best in class” manufacturing facility in full compliance with current good manufacturing practices (cGMP). This case history discusses our efforts to design, commission and meet both the letter and spirit of FDA regulations.
Design of a New Facility The cGMP regulations, as they are written, apply to the manufacture of drugs in their final dose form, but the FDA applies the regulations to the manufacture of bulk APIs. In addition, they also apply these regulations to the manufacture of drug intermediates if the manufacture of an intermediate is a “critical” step. They define a critical step as one that affects part of the drug’s characterization, such as its crystalline form or impurity profile. Much of the cGMP regulations address architectural or civil engineering issues such as requirements for adequate lighting and waste water drainage. Lights and electrical fixtures must be cleanable, or else placed in recessed enclosures. All incoming raw materials must be approved and labeled by quality control (QC), which requires sufficient warehouse space to separate pre-approved raw materials (quarantined) from approved raw materials. Additional floor space is also required to allow segregation of quarantined and approved products and intermediates. The FDA is flexible with its requirements for the protection of product from contamination, allowing different levels of protection based on the level of product exposure and whether the exposure occurs at a pre-critical or a critical stage of manufacture. For example, if an existing chemical plant is being converted to manufacture APIs, temporary plastic curtains can be placed around reactors to provide isolation during times when the reactor is open (such as during the charging of solids through the manway or transfer of solids from the centrifuge to the dryer). However, in our case, we were building a new facility rather than attempting to convert an existing one. We chose to design the highest non-aseptic level of protection available and chose the suite design to maximize control and isolation of the product. Only one product is typically made in a suite at one time. Equipment rooms separate the suites (see Figure 1, p. 34 in printed version). All utilities, support equipment and electrical boxes are isolated in the equipment rooms, as much as smooth operation will permit; all wall penetrations are sealed. Filters are located on both vacuum and nitrogen lines. Each suite has a separate gowning room and materials staging room. Clean-room walls (which are epoxy coated), ceiling and floor allow vigorous cleaning with direct spray from a water hose. There is no piping or equipment above the reactor manways or dryer manway to accumulate dust and potentially contaminate the product. A dedicated HVAC system supplies air to each suite and provides a positive pressure to the suite to minimize outside contamination. The HVAC recycles air with either 95% or high efficiency particulate air (HEPA) filtration, depending on production requirements. Because recirculation of flammable vapors could potentially create a dangerous situation, lower explosive limit (LEL) sensors are located in the HVAC return air ducts. The air handler controller will automatically switch to full exhaust if flammable vapors are detected at a concentration of 25% or more of LEL. Although the first suite is under a positive pressure to the rest of the building, the second suite can be under either a positive or a negative pressure. A negative pressure is desirable when compounds such as radioisotopes or cytotoxic drugs are being manufactured. USP-grade water runs in a continuous loop from the holding tank, throughout the plant, and back to the holding tank. The recirculation pipe has “drops” at each point of use, but no deadlegs (dead-end pipes at least five pipe diameters long). The water entering the loop is treated with UV sterilization and 0.2µ filtration to remove bacterial contamination. This meets the requirement that water does not introduce contaminants into the product.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !